Eliem Therapeutics, Inc. (ELYM)
NASDAQ: ELYM · IEX Real-Time Price · USD
7.30
+0.53 (7.83%)
At close: Jul 19, 2024, 4:00 PM
8.13
+0.83 (11.37%)
Pre-market: Jul 22, 2024, 7:50 AM EDT
Company Description
Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems.
The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.
Eliem Therapeutics, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Aug 10, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc |
Contact Details
Address: 2801 Centerville Road 1st Floor, Pmb #117 Wilmington, Delaware 19808 United States | |
| Phone | 877-354-3689 |
| Website | eliemtx.com |
Stock Details
| Ticker Symbol | ELYM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.50 |
| CIK Code | 0001768446 |
| CUSIP Number | 28658R106 |
| ISIN Number | US28658R1068 |
| Employer ID | 83-2273741 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrew Levin M.D., Ph.D. | Principal Financial Officer and Executive Chairman |
| Dr. Valerie Morisset Ph.D. | Chief Scientific Officer and Executive Vice President of Research and Development |
| Emily Pimblett | Principal Accounting Officer |
| Jo Palmer-Phillips Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 12, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 2, 2024 | D | Notice of Exempt Offering of Securities |
| Jul 2, 2024 | D | Notice of Exempt Offering of Securities |
| Jul 2, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jul 1, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jun 27, 2024 | 8-K | Current Report |
| Jun 26, 2024 | 8-K | Current Report |
| Jun 14, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 12, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 12, 2024 | 8-K | Current Report |